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Abstract
Background: We recently developed a new method to induce human stem cells (hESCs) differentiation into
hematopoietic progenitors by cell extract treatment. Here, we report an efficient strategy to generate erythroid
progenitors from hESCs using cell extract from human fetal liver tissue (hFLT) with cytokines. Human embryoid
bodies (hEBs) obtained of human H1 hESCs were treated with cell extract from hFLT and co-cultured with human
fetal liver stromal cells (hFLSCs) feeder to induce hematopoietic cells. After the 11 days of treatment, hEBs were
isolated and transplanted into liquid medium with hematopoietic cytokines for erythroid differentiation.
Characteristics of the erythroid cells were analyzed by flow cytometry, Wright-Giemsa staining, real-time RT-PCR
and related functional assays.
Results: The erythroid cells produced from hEBs could differentiate into enucleated cells and expressed globins in
a time-dependent manner. They expressed not only embryonic globins but also the adult-globin with the
maturation of the erythroid cells. In addition, our data showed that the hEBs-derived erythroid cells were able to
act as oxygen carriers, indicating that hESCs could generate functional mature erythroid cells.
Conclusion: Cell extract exposure with the addition of cytokines resulted in robust erythroid -like differentiation of
hEBs and these hEBs-derived erythroid cells possessed functions similar to mature red blood cells.
Background
Red blood cells (RBCs) have been utilized as the treat-
ment for severe blood loss and hematopoiesis study; but
their clinic application has been constrained by limited
quantities and compatibility issues. The availability of
hESCs offers a great opportunity to produce large quan-
tities of erythroid cells in vitro for transfusion, and to
provide additional knowledge to the field of erythropoi-
esis. Previous studies have generated primitive erythroid
cells from hESCs by embryoid body formation and stro-
mal cell co-culturing [1-7]. However, the risk of mouse-
related diseases and the low differentiation efficiency of
hESCs are major limitations of the clinical application of
this study.
Recently, we have established a method to produce rela-
tively large number of human hematopoietic cells from
hESCs, via a human-derived induction system, by using
hFLSCs feeder cells and cell extract of hFLT. Use of this
culture method enabled the production of 32.73% CD34
+
from treated hEBs after 11 days of culture. More impor-
tantly, hEBs-induced hematopoietic cells predominantly
yielded erythroid precursors when seeded on methylcellu-
lose [8]. Based on the above results, we isolated the 11-
day hEBs from the co-culture system and transplanted
them into liquid medium for a 16-day extending culture.
During the 16-day culture, cytokines are used to first pro-
mote the proliferation and subsequently used for the
maturation of erythroid precursors. This culture method
enabled the production of about 5 × 10
6 fully differen-
tiated erythroid cells from about 5 × 10
4 hEBs. The ery-
throid cells morphologically resembled fetal liver-derived
erythroblasts, they mainly expressed embryonic hemoglo-
bin and could be enucleated. Our results show that induc-
tion of hESCs into mature erythroid cells in vitro is
possible by treatment with cytokine-supplemented cell
extract.
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The effects of hFLT cell extract treatment on hEBs
After culture on low-attachment plates for about
24 hours, flat hESCs differentiated into typically round
hEBs. The permeabilization of hEBs was analyzed with
the streptolysin-O (SLO) assay. In a previous study, we
f o u n dt h a tm o s th E B sc o u l db el a b e l e dw i t hT e x a sR e d
containing 700 ng/ml SLO [8], therefore we chose to
incubate hEBs with 700 ng/ml SLO for 50 min in this
experiment. After incubation, the permeabilized hEBs
were exposed to hFLT cell extract. To reseal cellular
plasma membranes, cells were then cultured in IMDM
containing 10% fetal calf serum (FCS) and 2 mM CaCl2.
(Figure 1)
The capacity of erythroid-like development of hEBs
In a previous study, we found that cell extract treatment
could influence differentiation of hEBs but only hFLT
cell extract treatment could improve hematopoietic dif-
ferentiation of hEBs [8]. This experiment provided an
opportunity to conduct a large-scale investigation of
hESCs-derived erythropoiesis after hFLT cell extract
treatment. Firstly, we treated hEBs with hFLT cell
extract as described previously [8]. Then the treated
hEBs were co-cultured on the hFLSCs feeder in hEBs
differentiation medium for the hematopoietic differentia-
tion, and the untreated hEBs were culture in the same
condition as a control.
To examine the capacity for erythroid development of
hEBs, the cells were analyzed by hematopoietic colony
assays, and colonies were scored according to their cel-
lular morphology. Our results showed that, for
untreated hEBs, the colony-forming cells (CFCs) were
first found in the day-6 hEBs and various types of hema-
topoietic CFCs increased rapidly afterwards, including
colony-forming units-granulocyte-macrophage (CFU-
GM), colony-forming units- macrophage (CFU-M), col-
ony-forming units-erythroid (CFU-E) colonies, and they
reached a peak in day-14 hEBs. As shown in Figure 2,
most of the hematopoietic colonies were CFU-GM. At
the peak (day 14), about 1 × 10
5 untreated hEBs-derived
cells generated 315.2 ± 25.3 hematopoietic colonies, of
which about 55% were CFU-GM and about 22% were
erythroid bursts. For hFLT cell extract treated hEBs,
hematopoietic colonies were first detected in day-3 hEBs
and they reached a peaked on day 11. The number of
colony-forming cells produced from the treated hEBs
was much greater than that from untreated. At the
peak, about 1 × 10
5 untreated hEBs-derived cells could
generate 655.2 ± 31.3 hematopoietic colonies. Interest-
ingly, hFLT cell extract exposure had a greater effect,
both number and frequency, on erythroid colony forma-
tion of hEBs. The frequency of CFU-E colonies reached
62% on day 11 of hEBs (Figure 2). Altogether, these
data suggested a supportive role of hFLT cell extract on
the erythroid lineage development at the clonal level.
The effects of hFLT cell extract treatment on gene
expression
To understand the effects of hFLT cell extract treatment
on gene expression, we investigated the erythroid asso-
ciated genes of hEBs at different days of co-cultures
including SCL, Gata-2, Gata-1, EKLF by RT-PCR. We
found that the exposure to hFLT cell extract could pro-
mote the erythroid associated gene expression (Figure 3).
After incubation with hFLT cell extract, SCL was first
detected as early as day 2 and Gata-1 was expressed by
d a y4 ,t h i sd a t ac o n f i r m e do u rp r e v i o u sr e p o r t[ 8 ] .T h e
EKLF mRNA was detectable by day 4 of differentiation,
and its expression was persistently high throughout the
remaining of time course. Gata-2 was obviously expressed
by day 8 and up-regulated from day 10. However, for
untreated hEBs, SCL could be first detected by day 4 and
Gata-1 could be found by day 8 at a low level. The other
erythroid-associated genes that were tested were difficult
to detect before day 12 in the untreated group.
Production of red blood cells from hEBs
Our data confirmed that hEBs treated with hFLT cell
extract possessed a good capacity for erythroid lineage
development, and the 11-day hEBs could yield the greatest
number of erythroid colonies. To generate a large-scale of
Figure 1 The inducing system to produce erythroid cells from hEBs. Step1. hEBs were treated by hFLT cell extract. Step2. The treated hEBs
were co-cultured with hFLSCs feeder. Step3. Erythroid differentiation of hEBs in liquid medium with cytokines.
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Page 2 of 9erythroid cells from hESCs, we isolated the 11-day treated
hEBs and plated cells in liquid medium. Since bone mor-
phogenetic protein-4 (BMP-4) and Flt-3 ligand (Flt-3l)
could promote expanding capacity of hematopoietic cells,
so cells were incubated with BMP4 (20 ng/mL), stem cell
factor (SCF, 100 ng/mL), erythropoietin (EPO, 2 U/mL)
and Flt-3l(20 ng/mL) from day 1 to day 8. Insulin like
growth factor-1 (IGF-1) was necessary for normal ery-
throid differentiation[9,10], so erythroid progenitors cells
were stimulated by incubation with IGF-1 (20 ng/mL),
SCF (100 ng/mL), EPO (4 U/mL)from day 9 to day 16.
The number of cells was counted during the 16-day liquid
culture period. The results showed that the cells expanded
rapidly from day 1 to day 8 and the number of cells
increased from 50,000 to 5000,000 per well of 24-well
plate. However, the cell numbers did not increase from
day 9 to day 16. So about 50,000 hEB cells could yield
about 5000,000 erythroid cells during a 16-day incubation,
which implied a 100-fold amplification of the erythroid
cells produced from the EB cells. (Figure 4A).
To monitor the differentiation of hEB cells into ery-
throid cells, CD71 (transferrin receptor) and glycophorin
A (GLA) antigens were examined by flow cytometry
assay throughout the culture. At the beginning of the
liquid culture, CD71
+ cells were detected at a low lever
and GLA
+ cells could not be detected at all (data not
Figure 2 Generation of colonies from co-culture system. (A)Statistical analysis for the different kinds of blast colonies generated from treated
and untreated hEBs at different day. The data represent the mean ± SEM from three experiments. *, P < 0.05 when colonies generated from
treated hEBs were compared with colonies generated from untreated hEBs at the same day. (B)Typical CFU-GM, CFU-Mix, and CFU-E colonies
derived from hEBs after being seeded in methyl-cellulose. Scale bar, 100 um.
Figure 3 The gene expression of hEBs. RT-PCR analysis the erythropoietic markers (Gata-2, Gata-1, SCL, EKLF) of treated and untreated hEBs at
different days.
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Page 3 of 9Figure 4 The production of erythroid cells from treated hEBs. (A)Amplification of erythroid cells in liquid culture.50000 hEB cells from co-
culture could yield about 5000,000 erythroid cells in liquid medium.(B) Analysis of erythroid differentiation of treated hEBs by flow cytometry.
Erythroid cells derived from treated hEBs were seeded in liquid medium and tested for expression of CD71 (the marker of early erythroid), GLA
(the marker of matuered erythroid) cells by flow cytometry at different inducing times. (C)Statistical analysis for the cell surface antigen
expression of hEBs-derived erythroid cells in liquid medium. The data represent the mean ± SEM from three experiments. *, P < 0.05 when
compared with the average expression of CD71 or GLA at day 4.
Liu et al. BMC Developmental Biology 2010, 10:85
http://www.biomedcentral.com/1471-213X/10/85
Page 4 of 9shown). CD71
+ cells increased rapidly from day 1 to day
8, and reached 89.63% of their peak level at day 8 and
subsequently decreased. About 34% of the cells were
CD71
+cells at the day 16. In contrast, however, GLA
+
cells expanded significantly from day 8 to day 16. GLA
+
cells could not reach 30% at the day 8, but peaked
51.82% at the end of culture (Figure 4B, C)
Analysis of hEBs-derived erythroid cells
To further characterize the erythroid cells derived from
hEBs, we stained cells with Wright-Giemsa reagents and
compared them with RBCs derived from human fetal
liver. We found that hFLT cell extract treatment plus
cytokines promoted enucleation of hEBs-derived
erythroid cells. As shown in figure 5, the enucleated
hEBs-derived RBCs were first detected at day 8 in liquid
medium and approximately 20% to 35% of erythroid
cells were enucleated at day 16.
We next examined globin expression patterns of these
erythroid cells generated from hEBs after 4, 8, 12 or 16
days of culture by real-time PCR(Figure 6A). Then we
found that the cells derived from treated hEBs expressed
embryonic globins (ζ, ε, a and g)b u tn o ta d u l tg l o b i n s
(b) at the beginning of culture. The expression of ζ and
ε-globins mRNA increased rapidly from day 1 to day 8,
subsequently peaked at day 8 and then decreased. The
expression of a and g-globins mRNA peaked at day 12.
In contrast, the expression of b-globin was first detected
at day 16 at a low level.
To further observe the expression pattern of globins,
we analyzed hEBs-derived erythroid cells at different
days by western blotting. We found ζ, ε, a and g globins
proteins were detected by day 4 and b-globin protein
could be found at day 16 (Figure 6B), which confirmed
that erythroid cells generated from hEBs possessed the
capacity to express the adult globin at the end of cul-
ture. These data indicated that globins expression of
erythroid cells generated from hEBs might begin to
switch from the embryonic to the adult type at day 16.
Functional analysis of hEBs-derived erythroid cells
To assess the function of the hEBs-derived erythroid
cells, we measured oxygen dissociation of hEBs-derived
erythroid cells and compared them with human cord
blood (hCB) and human adult peripheral blood. As
shown in Figure 6C, hEBs -derived erythroid cells dis-
played an oxygen dissociation curve similar to that of
hCB, but shifted to the left as compared to the curve of
human adult peripheral blood.
Discussion
In this study, we first established a system to induce
the production of a large number of erythroid cells
from hESCs utilizing four standard procedures. In the
first and second steps, the hEBs were treated with the
cell extract from 14-weeks fetal liver and co-cultured
with hFLSCs feeders. Cell extract treatment is a novel
trans-differentiation strategy that can convert a
somatic cell type into another type [11-15]. We
recently reported a new method to promote the differ-
entiation of human stem cells toward hematopoietic
lineages by the treatment with cell extract of hFLT [8].
The fetal liver is a very important organ of human
hematopoiesis, and can generate not only transplanta-
ble hematopoietic stem cells, but also enucleated
RBCs. We therefore speculated that hFLT cell extract
treatment may be advantageous for erythroid line
development as well. In the current study, we isolated
hEBs from co-cultures after treatment with hFLT cell
extract and examined their capacity for the erythroid
development at different period of time. At same time
the untreated hEBs were isolated from co-cultures as a
control. We found that the treated hEBs in the co-cul-
ture system could express the erythroid associated
genes and give rise to erythroid lineage colonies in
semisolid medium, whereas the untreated hEBs did not
express erythroid associated genes and mainly yielded
CFU-GM with the same experimental conditions.
Thus, our data provided strong evidence which shows
Figure 5 RBCs obtained in liquid medium. The erythroid cells derived from hEBs were stained by Wright-Giemsa reagents at different day (the
arrows directed enucleated cells). Scale bar, 100 um.
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Page 5 of 9Figure 6 The feature of hEBs-derived erythroid cells. (A) Real-time PCR analysis of the globins gene expression of erythroid cells generated
from hEBs after 4, 8, 12 or 16 days of liquid culture. *, P < 0.05 when compared with the average expression of ζ, ε, a, g globins at day 4 and b
globin at day 12. (B) Western blotting analysis of the globins protein expression of erythroid cells generated from hEBs at different day. (C)
Functional assays of hEBs-derived erythroid cells. Oxygen dissociation curves of RBCs derived from hEBs, hCB or adult blood.
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ated erythroid cells.
Furthermore, we isolated the treated hEBs from co-
cultures and induced them into erythroid cells in two
-phases. At the beginning of the culture, addition of
BMP4, Flt-3l, SCF, and EPO resulted in a rapid increase
in cell numbers and an accumulation of differentiated
cells. CD71 was used as a marker for early erythroid
cells and GLA used as a marker for mature erythroid
cells. During the first stage of liquid culture, we
observed an obvious increase of CD71
+ cells and a slight
increase of GLA
+ cells, which implied the generation
and expansion of early erythroid cells from hEBs. From
day 9 to day 16, stimulated by IGF-1, SCF and a high
dose of EPO, most of the cells had characteristics of
mature erythroid cells. During this stage we observed a
peak in the percentage of GLA
+ cells, but the percentage
of CD71
+ cells decreased at the end of culture.
To further understand the erythropoiesis of hESCs, we
examined globins expression of erythroid cells from
hEBs. According to our previous study, erythroid cells
derived from hEBs only expressed embryonic globins but
not adult globin [5]. However, in this study we found
that hEBs-derived erythroid cells expressed both the
embryonic and adult globins at the end of culture. One
possible explanation for this result relates to the complex
process of mammalian erythropoiesis. In the primitive
hematopoiesis wave, blood islands in the yolk sac transi-
ently generate nucleated RBCs. In the later stage of devel-
opment, the fetal liver is the primary site for production
of transplantable hematopoietic stem cells and enu-
cleated RBCs. Definitive hematopoiesis ultimately shifts
t ot h eb o n em a r r o w ,t h es i t ef o rp r o d u c t i o no fl i f e - l o n g
adult-type hematopoiesis[2]. Erythrocytes from different
hematopoietic sites expressed different types of globins.
Yolk sac-derived erythrocytes express only embryonic
globins, and erythroblasts produced in fetal liver express
embryonic globins and a small amount of adult globin.
Erythroblasts from bone marrow primarily expressed
adult globin. In our inducing system, hEBs were treated
with hFLT cell extract and co-cultured with hFLSCs. It is
possible that this condition mimics the environment of
the fetal liver and results in similar globin expression of
the hEBs-derived erythroid cells as with fetal liver-
derived erythroid cells.
A critical issue for clinical application of hESCs is
whether they can generate functionally mature progenies.
In our system, enucleated RBCs could first be observed
at day 8 of liquid culture. The number of enucleated
RBCs increased rapidly from day 12 to 16. The erythroid
cells produced from treated hEBs morphologically
resembled RBCs from human fetal liver. Capability of
c a r r y i n go x y g e ni sa ni m p o r t a n tf u n c t i o no fR B C s .T o
determine if hEBs-derived erythroid cells possessed the
same function as normal RBCs, we analyzed the function
of hEBs-derived erythroid cells and found that the oxygen
dissociation curve of hEBs-derived erythroid cells shifted
to left compared to the curve of human adult blood. To
our knowledge, the oxygen dissociation curve of hCB was
shifted left when compared to that of human adult per-
ipheral blood [16]. Our results implied that hEBs-derived
erythoid cells were also able to function as oxygen car-
riers and the oxygen dissociation pattern of these cells
was more similar to fetal blood cells than adult blood
cells. Thus RBCs derived from hEBs in our system may
act as an alternative resource of RBCs from blood.
Conclusion
Hematopoietic differentiation of hESCs has been achieved
by using a variety of experimental approaches[1,2]. In
addition, the successful derivation of RBCs from hCB has
been achieved by many published assays[3,4]. However,
there are only a few published reports on erythroid differ-
entiation from hESCs. Trans-differentiation of a somatic
cell type into another cell type would be beneficial for pro-
ducing replacement cells for potential therapeutic applica-
tions. In this study, we first reported that fetal liver cell
extract-based treatment induced the differentiation of
hESCs into RBCs safely and efficiently. Our method pro-
vides a useful tool for studying the molecular mechanisms
of hematopoietic development, and will be valuable in the
production of RBCs for transfusion.
Methods
Cell culture
hESC H1 cells were obtained from WiCell Research
Institute, Inc. (Madison, WI, USA). To prevent cells
from differentiating, cells were co-cultured with irra-
diated (20 cGy) mouse embryonic fibroblast (MEF) cells
and maintained in knock-out Dulbecco’sm o d i f i e d
Eagle’s medium (DMEM) supplemented with 20%
serum replacer (SR), 1% nonessential amino acids
(NEAA), 1 mM L-glutamine (all from Invitrogen Cor-
poration, Carlsbad, CA, USA), 0.1 mM b-mercaptoetha-
nol (Sigma-Aldrich, USA) and 4 ng/ml human basic
fibroblast growth factor (bFGF) (R&D Systems, USA).
The hFLSCs were isolated and cultured as previously
described [17].
Preparation of cell extract
The hFLT cell extract was prepared, as described pre-
viously [18,19], from 15-week human aborted fetal liver
tissue obtained with informed consent. Briefly, the hFLT
cell extract was prepared as follows: cells were washed in
phosphate-buffered saline (PBS) and resuspended in cell
lysis buffer. Cells were lysed with a dropping pipette and
centrifuged at 15,000 × g for 15 minutes at 4°C. The
supernatant was removed, filtered and stored at -80°C.
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Step 1. Cell Extract treatment of hEBs
Undifferentiated hESCs were harvested at 80% confluence
after collagenase IV digestion and transferred to 10-cm low
cell-binding dishes to form hEBs in hEBs medium contain-
ing KO-DMEM supplemented with 20% FBS, 1% NEAA, 1
mM L-glutamine, and 0.1 mM b-mercaptoethanol. The
hEBs were then treated with hFLT extract. Briefly, the 2-
day hEBs were treated with SLO in Ca
2+-Mg
2+-free Hanks’
balanced salt solution (Gibco-BRL, Invitrogen) for 50 min-
utes at 37°C. About 100 μl of hFLT cell extract containing
an XX ul or % ATP-generating system (1 mM ATP, 1 mM
GTP, 1 mM NTP, 10 mM phosphocreatine, and 25 μg/ml
creatine kinase, Sigma) were added to replace the SLO and
incubated for 60 minutes at 37°C. To reseal plasma mem-
branes CaCl2 (2 mM) was added to the hESCs culture
medium, and cells were cultured overnight at 37°C.
Step 2. hFLSCs feeder co-culture
The treated hEBs were cultured with hFLSCs feeder in
hEBs differentiation medium for 11 days containing 80%
IMDM (Invitrogen), 30% FBS (Invitrogen), 1% NEAA, 2
mM L-glutamine, 0.1 mM beta-mercaptoethanol. After
some days of culture, cells were collected and analyzed to
identify erythroid differentiation. Total RNA was isolated
from hEBs at different days of co-culture using the fol-
lowing the manufacturer’s protocol. We analyzed mRNA
expression for markers of erythroid cells by RT-PCR. In
addition, the EB cells at different days of co-culture were
collected and seeded in MethoCult GF -H4434 semisolid
medium (Stem Cell Technologies, USA) to determine
their capacity for erythroid development.
Step 3. Erythroid differentiation of hEBs in liquid medium
with cytokines
The hEBs that possessed the greatest capacity for ery-
throid development were dissociated into single-cell
suspensions by collagenase IV treatment. Cells were
induced into erythroid cells by two phases: from day 1 to
day 8, cells were cultured in medium composed of
IMDM supplemented with 30% FBS, BMP4 (20 ng/mL),
SCF (100 ng/mL), EPO (2 U/mL), and Flt-3l(20 ng/mL);
from day 9 to day 16, cells were cultured in medium
composed of IMDM supplemented with 30%FBS, IGF-1
(20 ng/mL), SCF (100 ng/mL), EPO (4 U/mL). About 1
to 2 mL fresh medium was added to each plate every 2 to
3 days,.
RT-PCR
T h eg e n ee x p r e s s i o no fh E B sw a se x a m i n e db yR T - P C R .A l l
PCR reactions were performed as follows: 95°C for 5 min;
94°C for 40 s; annealing at various temperatures for 40 s,
72°C for 40 s (25 cycles); 72°C for 10 min, 4°C for 5 min.
The forward and reverse primers are shown in Table 1:
Clonogenic progenitor cell assay
Hematopoietic clonogenic assays were performed in 35-
mm low adherent plastic dishes using MethoCult GF
-H4434 semisolid medium (Stem Cell Technologies,
USA) consisting of 1% methylcellulose, 30% FBS, 1%
bovine serum albumin (BSA), 50 ng/mL stem cell factor,
20 ng/mL granulocyte-macrophage colony-stimulating
factor (GM-CSF), 20 ng/mL IL-3, 20 ng/mL IL-6, 20 ng/
mL granulocytecolony-stimulating factor (G-SF), and 3
units/mL erythropoietin(EPO). After culturing for 12-14
days, colonies were scored according to their cellular
morphology.
Real-Time PCR
The expression of globins in erythriod cells was exam-
ined by real-time RT-PCR using the SYBR Green PCR
Master Mix. All PCR reactions were performed as fol-
lows: 95°C for 5 min; 94°C for 40 s; annealing at various
temperatures for 40 s, 72°C for 40 s (25 cycles); 72°C for
10 min, 4°C for 5 min. The forward and reverse primers
used were described in Table 2 as follows:
Western blotting
The cell extract was subjected to sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred onto a polyvinylidene difluoride membrane
Table 1 Primer sequences for RT-PCR
Name Primer sequence (sense) Primer sequence (antisense)
Gata-1 CAGGTACTGCCCATCTCTAC TCTGGCTACAA G AGGAGAAG
Gata-2 AAGGCTCGTTCCTGTTCAGA GGCATTGCACAGGTAGTGG
SCL GCTGGCTTTTCTGTTTCCTG TGACA ACCCCAGGTCTTA GG
EKLF CGGACACACAGGATGATCTC GGCTGGTCCTCAGACTTCAC
b-Actin GATCCACATCTGCTGGAAGG AAGTGTGACGTTGACATCCG
Table 2 Primer sequences for Real-time PCR
Name Primer sequence (sense) Primer sequence (anti-sense)
ζ-globin GCTCAGGCCGAGCCCATTGG TAGCGGTACTTCTCAGTCAG
ε-globin GGAGAGTCCATTAAGAATCTA CTGTGAATTCATTGCCGA AGT
a-globin CGGTCAACTTCAAGCTCCTAAG CCGCCCACTCAGACTTTATT
b-globin TACATTTGCTTCTGACACAAC ACAGATCCCCAAAGGAC
g-globin CTTCAAGCTCCTGGGAAATGT GCAGAATAAAGCCTACCTTGAAAG
GAPDH CTGACTTCAACAGCGACACC TGCTGTAGCCAAATTCGTTGT
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taining 5% dry-fat skim milk, the membrane was incu-
bated with anti-globin antibodies (Santa Cruz
Biotechnology), followed by HRP-labeled goat anti rabbit
IgG. The protein bands were visualized by enhanced
chemiluminescence (ECL; Pierce).
Flow cytometric analysis
The trypsinized individual cells were incubated with the
following FITC-conjugated and PE-conjugated monoclo-
nal antibodies: anti-human CD71, anti-human glyco-
phorin A (B&D Biosciences, USA) for 30 minutes at 4°
C. Cells were washed with PBS for three times, and ana-
lyzed by flow cytometeric analysis using the FACSCali-
bur (Becton-Dickinson, Mountain View, CA, USA).
Wright-Giemsa staining
Cells were dropped onto slides and fixed for 20 minutes
in 4% paraformaldehyde and were stained with Wright-
Giemsa reagents (Fisher Scientific) following manufac-
turer’s instructions.
Functional Assays for Erythroid Cells
The oxygen binding ability of hESCs-derived erythroid
cells and human adult blood was measured with a
Hemox analyzer, as reported previously [20,21].
Statistical analysis
Results were expressed as means ± SEM. Statistical sig-
nificance was determined using Student t- test. Results
were considered significant at P < .05.
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